CircRHOBTB3 Restricts Prostate Cancer by Sequestering NONO

Study Background and Research Question

Prostate cancer (PCa) remains among the most prevalent malignancies affecting men globally, with metastatic prostate cancer (mPCa) posing a significant clinical challenge due to its poor prognosis and limited curative options. Delayed diagnosis frequently leads to advanced disease, underscoring the urgent need for molecular insights to inform early intervention and new therapeutic targets (Cancer Letters 2025). While circular RNAs (circRNAs) were once considered non-functional byproducts, emerging evidence highlights their regulatory roles in gene expression, cancer progression, and cellular compartmentalization. However, the mechanistic contributions of specific circRNAs in PCa, especially in metastatic contexts, have remained poorly characterized.

Key Innovation from the Reference Study

The referenced study by Song et al. (Cancer Letters 2025) makes a pivotal advance by identifying hsa_circ_0007444—hereafter termed circRHOBTB3—as a functionally significant circRNA in prostate cancer. Through integrative analyses using both high-throughput sequencing of highly metastatic PCa cell models and clinical PCa tissues, the authors found circRHOBTB3 to be markedly downregulated in cancerous samples. Importantly, its low expression correlated with more aggressive pathological features, such as higher T and M stages and elevated D’Amico grade, suggesting a pronounced tumor-suppressive role.

Methods and Experimental Design Insights

The research team employed a robust, multi-tiered approach to elucidate circRHOBTB3’s function and mechanism:

• Model Development: Highly metastatic (HM) PCa cell models were generated to compensate for the scarcity of patient-derived mPCa tissues, providing a controlled system to dissect molecular events underlying metastasis.
• Transcriptome Analysis: High-throughput sequencing allowed for the identification and quantification of circRNA expression profiles, with cross-validation in both HM cell models and clinical samples.
• Functional Assays: In vitro and in vivo experiments assessed the effects of circRHOBTB3 overexpression or knockdown on PCa cell proliferation, migration, and metastatic potential.
• Protein-RNA Interaction Studies: Immunoprecipitation and fluorescence in situ hybridization (FISH) were used to confirm circRHOBTB3’s interaction with the non-POU domain-containing octamer-binding protein (NONO).
• Downstream Pathway Analysis: Chromatin immunoprecipitation (ChIP) and expression assays elucidated the impact of circRHOBTB3-NONO interactions on monoamine oxidase A (MAOA) transcription.
• Circularization Regulation: The role of the splicing factor serine/arginine-rich splicing factor 9 (SRSF9) in circRHOBTB3 biogenesis was explored by mapping its binding to Alu elements and testing the effect on circRNA formation.

Protocol Parameters

• assay | qRT-PCR quantification | ng RNA/sample | applicable for circRNA expression measurement in PCa cell lines and tissues | standardized method for sensitive detection | paper
• assay | FISH for subcellular localization | 100–500 nM probe | mapping circRNA compartmentalization in cell models | resolves cytoplasmic vs. nuclear localization | paper
• assay | Immunoprecipitation for RNA-protein binding | 1–5 μg antibody per 10⁶ cells | applicable for identifying circRNA-protein complexes | validates direct physical interaction | paper
• assay | Cell proliferation assay (e.g., MTT or CCK-8) | 1–10⁴ cells/well | evaluates functional impact of circRNA manipulation | quantifies proliferation changes | paper
• assay | In vivo xenograft tumor models | 10⁶ cells/injection | applicable for translation of in vitro findings to animal models | measures tumorigenicity and metastatic potential | paper
• assay | siRNA or shRNA knockdown | 10–100 nM | workflow_recommendation | optimal range to suppress target gene in PCa cells | workflow_recommendation

Core Findings and Why They Matter

The central discovery is that circRHOBTB3 acts as a tumor suppressor in prostate cancer by regulating the subcellular localization of NONO, a transcriptional activator of MAOA:

• Expression Patterns: circRHOBTB3 levels are significantly reduced in PCa tissues and cell lines compared to non-cancerous controls (Cancer Letters 2025).
• Functional Impact: Overexpression of circRHOBTB3 inhibits PCa cell proliferation and metastatic behavior both in vitro and in animal models, while knockdown has the opposite effect.
• Molecular Mechanism: circRHOBTB3 binds NONO in the cytoplasm, preventing its nuclear translocation. This sequestration reduces NONO-driven MAOA transcription, resulting in decreased MAOA levels—an effect linked to impaired PCa cell growth and invasiveness.
• Regulation of Circularization: The formation of circRHOBTB3 itself is negatively regulated by SRSF9, which binds Alu elements and suppresses back-splicing. This adds a further regulatory layer to circRHOBTB3 availability and function.

Collectively, these findings position circRHOBTB3 as a dual-level regulator in PCa: it is both subject to splicing factor-mediated control and an active modulator of tumorigenic transcriptional programs via NONO and MAOA.

Comparison with Existing Internal Articles

This mechanistic model—where a non-coding RNA modulates cancer cell behavior via protein sequestration and downstream transcriptional repression—shares conceptual parallels with studies targeting receptor tyrosine kinase (RTK) pathways in oncology. For example, multitargeted RTK inhibitors such as Dovitinib (TKI-258, CHIR-258) are employed to disrupt oncogenic signaling cascades in multiple myeloma, hepatocellular carcinoma, and other cancers (internal review). These inhibitors induce apoptosis and suppress proliferation by blocking phosphorylation events and downstream effectors, such as ERK and STAT proteins, mirroring the inhibitory logic of circRHOBTB3 on MAOA-mediated pathways.

Further, internal articles like "Optimizing Cell-Based Cancer Assays with Dovitinib" detail how multitargeted RTK inhibitors are integrated into cell viability and apoptosis induction workflows, offering experimental blueprints that could inform the design of circRNA-targeted intervention studies. While the molecular targets differ—circRHOBTB3 acts at the RNA-protein interface, while Dovitinib affects kinases—the underlying goal of disrupting pro-tumorigenic signaling is shared. These strategic overlaps highlight the translational potential for combining circRNA-based approaches with established kinase inhibition strategies in future research.

Limitations and Transferability

While the study provides compelling evidence for the tumor-suppressive role of circRHOBTB3, several limitations merit consideration:

• Model Specificity: The heavy reliance on cell line models and xenografts, although necessary due to tissue scarcity, may not fully recapitulate human metastatic microenvironments. Validation in larger, clinically diverse cohorts is needed.
• Mechanistic Breadth: The study focuses on the NONO-MAOA axis, but circRHOBTB3 may regulate additional pathways or interact with other proteins in PCa cells.
• Therapeutic Translation: While the findings nominate circRHOBTB3 as a biomarker and potential therapeutic target, the delivery and specific modulation of circRNAs in vivo remain technically challenging and are not yet ready for clinical application.

Transferability to other cancer types or disease models should be approached cautiously, as circRNA expression and function are often tissue- and context-specific (Cancer Letters 2025).

Research Support Resources

For researchers aiming to dissect circRNA functions or evaluate combinatorial strategies targeting oncogenic signaling, robust experimental toolkits are essential. In cell-based workflows investigating apoptosis induction in cancer cells or inhibition of ERK and STAT signaling pathways, validated reagents such as Dovitinib (TKI-258, CHIR-258) (SKU A2168) from APExBIO offer a reliable standard for multitargeted RTK inhibition (workflow_recommendation). This compound, widely used in multiple myeloma research and hepatocellular carcinoma treatment research, can be integrated into assays to benchmark or contrast the efficacy of novel circRNA-targeted approaches. Protocols typically involve preparing stock solutions in DMSO and using citrate buffer for in vivo work, aligning with standard signal transduction and apoptosis research practices (product_spec).